彩色多普勒超声对乳腺癌新辅助化疗疗效的评价研究

目的:探讨彩色多普勒超声(CDFI)对乳腺癌新辅助化疗(NCT)疗效评价的临床应用价值。方法:选取2013年1月~2013年12月在我院接受新辅助化疗后行手术治疗的女性乳腺癌患者55例,以病理学评价为金标准,化疗后根据化疗效果分为有效组和无效组,利用CDFI观察患者NCT前后病灶超声指标、病灶内血流分级及阻力指数(RI)值变化。结果:55例患者中,临床触诊疗效评价符合率为36.4%,敏感度为60.7%;CDFI评价符合率为70.9%,敏感度为85.7%。CDFI检查显示,乳腺癌NCT后原发肿瘤病灶大小显著缩小,边界多清晰可见,内部回声及后方回声倾向正常。有效组NCT前后病灶内的血流类型和RI值变化有统计学意义(P0.05),无效组NCT前后病灶内的血流类型和RI值无明显变化(P0.05)。结论:CDFI技术可对乳腺癌NCT前后病灶大小及病灶内部血流动力学变化提供客观参数,是评价乳腺癌NCT疗效的有效方法。

Study of Color Doppler Flow Imaging in Evaluating Effect of Neoadjuvant Chemotherapy to Breast Carcinoma

Objective:To explore the value of the color Doppler flow imaging in ecaluating effect of neoadjuvant chemotherapy to breast carcinoma.Methods:Selected 55 women patients with breast cancer who received neoadjuvant chemotherapy,and underwent operation treatment in our hospital from January 2013 to December 2013, according to the pathological evaluation for the gold standard, the patients were divided into effective group and ineffective group according to the chemotherapy effect after chemotherapy. The index of ultrasound, the degree of blood flow and hemodynamics index of the tumor were observed by using color Doppler flow imaging.Results:The coincidence rate of clinical palpation for evaluating efficacy was 36.4%, the sensitivity was 60.7% in 55 cases; CDFI evaluation of the coincidence rate was 70.9%, the sensitivity was 85.7%. CDFI examination revealed, the border became more clearly, decrease of tumor lesion size, internal echo and rear echo tend to be normal after neoadjuvant chemotherapy. In effective group, the differences of the blood mode and RI value of the breast tumors between before and after chemotherapy were significant (P<0.05). In ineffective group, there was no significant difference in the blood mode and RI value of the breast tumors between before and after chemotherapy (P>0.05).Conclusion:The color Doppler flow imaging technology can provide objective parameters on lesion size and lesion internal hemodynamic changes before and after accepted neoadjuvant therapy in breast carcinoma, which is an effective method for evaluating the effect of neoadjuvant chemotherapy on breast carcinoma.